# Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

> **NCT06094868** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 45 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT06094868
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06094868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06094868, "Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06094868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*